Blog Big Molecule Watch January 04, 2022

Health Canada Approves Celltrion’s Adalimumab Biosimilar, YUFLYMA

According to various reports, Celltrion has received approval from Health Canada for YUFLYMA, a biosimilar of AbbVie’s HUMIRA product.  YUFLYMA was previously approved in Europe, and is a high-concentration, low-volume, citrate-free formulation of adalimumab.

The post Health Canada Approves Celltrion’s Adalimumab Biosimilar, YUFLYMA appeared first on Big Molecule Watch.